# NIH Reporter #1R43CA310210-01A1

Enhancing NK Cell Engineering Through Optimized SoftPoration(TM) for Cell-Based Therapeutics

**Recipient:** OpenCell Technologies, Inc.

**Award Amount:** $287,125.00
**Ceiling:** $287,125.00

**Awarded:** September 15, 2026

**Identifier:** 1R43CA310210-01A1

This award funds OpenCell Technologies to optimize their SoftPorationTM platform for engineering natural killer (NK) cells, aiming to improve cell-based cancer therapies by making the process faster, gentler, and more cost-effective.

### Description

OpenCell Technologies is developing a simple, gentle method to perform NK cell engineering, preserving cell health and functionality and minimizing both monetary and time costs. The SoftPorationTM platform enables quick, gentle, and efficient engineering of NK cells for therapeutic use, aiming to increase patient access to these treatments.

[View original record](https://reporter.nih.gov/search/IgE1H2ioLUOz0qmA4MDg0Q/project-details/11410082)